Halogen Bonding in Nucleic Acid Complexes by Kolář, Michal H. & Tabarrini, Oriana
Halogen Bonding in Nucleic Acid Complexes
Michal H. Kola´ˇr∗,†,¶ and Oriana Tabarrini‡
†Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences,
Flemingovo nam. 2, 16610 Prague, Czech Republic
‡Department of Pharmaceutical Sciences, Universita of Perugia, Via del Liceo 1, I-06123
Perugia, Italy
¶Current address: Department of Theoretical and Computational Biophysics, Max Planck
Institute for Biophysical Chemistry, Am Fassberg 11, D-37077 Go¨ttingen, Germany
E-mail: michal@mhko.science
Abstract
Halogen bonding (X-bonding) has attracted no-
table attention among noncovalent interactions.
This highly directional attraction between a
halogen atom and an electron donor has been
exploited in knowledge-based drug design. A
great deal of information has been gathered
about X-bonds in protein-ligand complexes, as
opposed to nucleic acid complexes. Here we
provide a thorough analysis of nucleic acid com-
plexes containing either halogenated building
blocks or halogenated ligands. We analyzed
close contacts between halogens and electron-
rich moieties. The phosphate backbone oxygen
is clearly the most common halogen acceptor.
We identified 21 X-bonds within known struc-
tures of nucleic-acid complexes. A vast major-
ity of the X-bonds is formed by halogenated
nucleobases, such as bromouridine, and feature
excellent geometries. Noncovalent ligands have
been found to form only interactions with sub-
optimal interaction geometries. Hence, the first
X-bonded nucleic-acid binder remains to be dis-
covered.
Introduction
Bringing a new drug to the market consumes
enormous intellectual and financial resources.
It typically takes more than a decade from the
discovery of an active compound (lead) to the fi-
nal approval of a drug, which is based on it. The
drug discovery and development declined from
the trial-and-error approach when the number
of recognized diseases steeply rose. Nowadays,
the workflow stems from knowledge gained in a
variety of studies believing that this can speed-
up the whole drug development.
The number of known drug targets is slightly
higher than 300.1 This amount is not extraor-
dinarily high bearing in mind the number of
recognized human genes (less than 20,0002).
Among the targets, there are mostly proteins
and only a few nucleic acids (NAs). Given that
NAs are ubiquitous biopolymers with a myriad
of cellular functions though, they represent a
clinically prominent class of targets.1
Many strategies have appeared to optimize
the lead compound into a therapeutic sub-
stance. The use of halogens is in this sense
traditional. Xu et al. estimated that about
25 % of approved drugs are halogenated, and
the portion is similar in all stages of drug dis-
covery and development.3 Halogen atoms mod-
ulate physicochemical properties of the molec-
ular scaffolds; they affect the polarity and hy-
dro/lipophilicity, which in turn changes mem-
brane and blood brain barrier permeation of the
molecule. Also, carbon-halogen covalent bond
is difficult to metabolize, so the halogenation
prolongs the lifetime of the active compound,
but at the same time might increase its liver
toxicity.4
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Apart from nonspecific effects, it was about
a decade ago recognized that halogens might
partake in a structurally specific and direc-
tional noncovalent interaction called a halogen
bond (X-bond).5 The X-bond is an interac-
tion between a halogen and a Lewis base or
an electron-rich moiety. The electron density
donors may be represented by electronegative
atoms such as oxygen, nitrogen, sulfur, but also
by aromatic rings or conjugated pi-systems.
The X-bond has been found in many protein-
ligand complexes including pharmaceutically
relevant ones (for review see Refs. 6, 7, and
8). There have been only a few studies on
X-bonds, where NAs played a role. The dis-
tinguished exceptions are the efforts of Shing
Ho and co-workers. They focused on halogen
bonding in so-called Holliday junction, a four-
stranded (branched) complex of deoxyribonu-
cleic acid (DNA).9,10 Using bromouridine as a
building block, they directed a DNA into one
of the several nearly isoenergetic conformers.11
The DNA model system also demonstrated that
among the halogens it is the bromine that has
the most favorable entropy/enthalpy compen-
sation. Consequently, bromine was claimed an
optimal element for X-bonding in DNA Holli-
day junctions.12,13
To the best of our knowledge, no ligand has
been reported so far to form an X-bond in any
NA complex. The lack of information on X-
bonding in NAs is somewhat surprising because
NAs are naturally rich in electronegative atoms
which make them (in theory) prospective X-
bond acceptors. It seems that there is a miss-
ing relation between the worlds of NAs and X-
bonds. This work aims at building such a rela-
tion. Hence, we continue with the introductions
of the two worlds trying to find some overlap be-
tween them and highlight the pharmaceutical
significance. Later, we analyze known struc-
tures of NAs and reveal main features of their
complexes. Finally, we discuss all of the few
examples of low-molecular compounds whose
halogens are involved in interactions with elec-
tron donors.
Halogen Bonding Features
The attraction of halogens with other elec-
tronegative atoms was observed as early as the
1950s in the crystallographic studies of Has-
sel et al.14 although the synthesis of X-bonded
complexes dates back to 19th century.15 The
puzzling nature of the attraction between two
electron-rich chemical groups was attributed
merely to charge transfer effects until Politzer
et al. came up with a simple model explain-
ing many of the X-bond features.16 Based on
quantum chemical calculations of the molecular
electrostatic potentials (MEPs) they proposed
that the surface of halogens contains regions of
both positive as well as negative electrostatic
potential (ESP).16 The positive region was la-
beled a sigma-hole (σ-hole) (Fig. 1), and in-
terestingly enough this label appeared only 15
years after its first evidence.17 The X-bond has
been exploited in many areas of chemistry and
material science (reviewed e.g. in Refs. 5 and
18) and a great amount of work has been done
on the theoretical aspects of X-bonds too.6,19
Figure 1: Molecular structure of bromouracil
(a), the intersection of a molecular surface (b),
and full ESP in atomic units (au) projected
onto the molecular surface (c). The blue disc
of positive ESP in the forefront is the σ-hole.
X-bonds are similar in strength to the more
common hydrogen bonds (H-bonds). The X-
bond stabilization energy typically amounts
to 5–25 kJ/mol20,21 and it increases with the
increasing atomic number of the halogen in-
volved.22 The reason for this is the increas-
ing size and magnitude of the halogen σ-hole.23
Another factor is the halogen polarizability,24
which also increases with the halogen atomic
number. Contrary to traditional view, mod-
ern theoretical studies suggest that the role
of charge transfer in the X-bond stabilization
is modest.25 The strongest X-bonds are found
2
in complexes of iodinated molecules; bromi-
nated and chlorinated molecules form weaker
X-bonds. Fluorine is the least polarizable and
the most electronegative halogen. It possesses
positive σ-holes in rare cases and mostly in in-
organic molecules,26 so it is of lower importance
for biological applications.
The structural trends of X-bonds in
biomolecules have been inferred from several
Protein Data Bank (PDB)27 surveys and the-
oretical analyses.7,28–30 All of the studies fo-
cused on protein-ligand X-bonds. The X-bonds
are mostly established with the protein back-
bone. Its carbonyl oxygen is the most frequent
electron donor.29 No preference for backbones
of α-helices, β-sheets or loop structures has
been found.31 Lu et al. reported that about
one-third of protein-ligand X-bonds involve an
aromatic ring of the amino acid side chains.29
It was also reported that the X-bonds might
not disrupt existing networks of H-bonds.32 In-
stead, an orthogonal pattern of X- and H-bonds
is preferred involving the same electron donor
atom.33 Another effect of ligand halogenation
is a shortening of proximal H-bonds.34
Nucleic Acids as Drug Tar-
gets
The deoxyribonucleic and ribonucleic acids
(DNA and RNA) appear in living organisms in
several forms. Whereas the DNA adopts only a
few conformational classes, the structural diver-
sity of RNA is much broader. DNA mostly oc-
curs in the B-form helical conformation. A key
RNA motif is the A-form double helix. How-
ever, loop regions, bulges, and other forms of
mismatched nucleobases often disrupt the mo-
tif. Such a conformational variability is mir-
rored in the rapidly expanding variety of RNA
functions recognized, especially in the last two
decades. Apart from the classic roles of riboso-
mal, transfer and messenger RNAs, RNA was
also shown to store genetic information, regu-
late gene expression, or act as enzyme.35,36
Many NA-binders are halogenated. The DNA
alkylating agents often contain halogen atoms
because halogens facilitate the alkylating reac-
tions on NAs. This way, anticancer cisplatin
and its analogues37,38 covalently modify DNA.
The reaction products block replication or tran-
scription processes. The effect of alkylation is
non-specific in terms of DNA sequence and also
cell type. The modifications occur in both nor-
mal and cancer cells, but the higher prolifera-
tion rate of the cancer cells makes these drugs
effective.
Alternatively to covalent modifications, var-
ious classes of compounds bind to double-
stranded DNA (dsDNA) in a noncovalent man-
ner. Examples include the anticancer anthra-
cycline type antibiotics daunomycin and adri-
amycin, and the polypeptide antibiotic dac-
tynomicin, which works mainly by intercalat-
ing into DNA. The intercalation, described
as an insertion of a planar molecule between
consecutive base pairs, interferes with DNA-
processing enzymes.39 Other small molecules
bind to dsDNA interacting with base pair func-
tional groups on the floor of the minor or ma-
jor groove. Much of the research has concen-
trated on the DNA minor groove recognition
leading to improved sequence selectivity of the
compounds.40,41
Important classes of drugs target ribosomal
RNA (rRNA). In fact, most of the RNA-
targeting drugs on the market act on ribo-
somes.42 The ribosome is a biomachine which
synthesizes proteins. As such, it represents
a critical center of cellular life. The differ-
ences between bacterial and eukaryotic ribo-
somes have allowed developing specific antibac-
terial agents that are often based on natural
products.43–45 There is a variety of binding lo-
cations within the ribosome; the most frequent
sites are the peptidyl-transferase center on the
50S subunit and the decoding center on the 30S
subunit. Aminoglycosides and tetracyclines are
the best-known classes of small molecules whose
primary target is the 30S subunit. Oxazoli-
donones instead exert their antibacterial action
by binding to the 23S rRNA present within
the 50S subunit. Macrolides and related com-
pounds (lincosamides and streptogramins), as
well as chloramphenicol and clindamycin also
target the 50S subunit. Several ribosome-
binding molecules have been prepared contain-
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ing a halogen atom stemming mostly from the
pioneering case study of chloramphenicol.46
In the past decade, other non-coding RNAs
(ncRNAs) have emerged as prospective drug
targets.42,47 Highly conserved ncRNAs provide
new opportunities to expand the repertoire of
drug targets to treat infections. Viral regula-
tory elements located in untranslated regions of
mRNA often form folded structures that harbor
potential binding sites for small molecules. The
absence of homologous host cell RNAs makes
them attractive for the development of innova-
tive antiviral compounds.
There are a plethora of ncRNAs under in-
tense pharmaceutical research due to their abil-
ity to interact with low-molecular ligands. For
instance, human immunodeficiency virus type-1
(HIV-1) Trans-activation response (TAR) RNA
plays an essential role in HIV-1 replication
through its interaction with the viral trans-
activator of transcription. Such interaction
might be disrupted by ligands (reviewed in
Refs. 48 and 49), where some of them contain
halogen atoms.50
Another example is an internal ribosome en-
try site (IRES) from Hepatitis C virus (HCV).51
The IRES RNA contains several independently
folding domains that are potential targets for
the development of selective viral translation
inhibitors. A diverse set of ligands includ-
ing oligonucleotides, peptides as well as small
molecules have been reported to block IRES
function by distinct mechanisms.52 Like in the
case of other ncRNAs, the drug candidates oc-
casionally contain halogens. Nevertheless, no
drug targeting a ncRNA has been approved for
the market.
Many lines of evidence are linking mutations
and dysregulations of ncRNAs to neurodegen-
erative disorders.53,54 The presence of expanded
CNG repeats in 5’ and 3’ untranslated regions
is related to important diseases such as My-
otonic dystrophy type 1, spinocerebellar ataxia
type 3, and fragile X-associated tremor-ataxia
syndrome. For example, the pathological ex-
pansion of CAG repeats (>35 consecutive CAG
codons) in huntingtin exon 1 encodes a mutant
protein whose abnormal function determines
Huntington’s disease. Finding compounds able
to bind pathogenic CNG repeats with high
specificity may be a valuable strategy against
these devastating diseases. Their design is still
limited by the lack of structural information,
although some small molecules have emerged
through various strategies.55,56
Both DNA and RNA can also adopt a
non-canonical higher-order structure called
G-quadruplexes (G4s) that are involved in
regulating multiple biological pathways such
as transcription, replication, translation and
telomere structure.57 The building blocks of
G4s are guanosine-rich quartets that self-
associate into a square-planar platform through
a cyclic Hoogsteen H-bonded arrangement. G4s
are found in oncogene promoters, in telomeres,
as well as in introns of mRNAs. These re-
gions have been recognized as potential targets
for anticancer drugs.58 A large number of small
molecules are able to bind the quadruplex struc-
tures. They are characterized by polycyclic
heteroaromatic scaffolds, or by cyclic/acyclic
non-fused aromatic rings. Thus far, only a few
molecules have been found to selectively bind
the telomeric G4s, although their therapeutic
potential appears high.59
Nucleic Acids as X-bond Ac-
ceptors
In the X-bond, the σ-hole on a halogen repre-
sents a Lewis acid that interacts with a Lewis
base. NAs seem to offer an abundance of ba-
sic chemical groups. The backbone contains
phosphate groups with two oxygens carrying a
charge of −1. Likewise, ribose and deoxyribose
contain oxygens with lone electron pairs that
could serve as σ-hole acceptors too. Further,
the nucleobases form H-bonds that could be po-
tentially replaced or augmented by X-bonds.
Nucleobases themselves show certain electro-
static diversity, where the negative sites may
play a role of halogen acceptors. Fig. 2 de-
picts MEPs of five most common nucleobases
projected onto the plane of their aromatic sys-
tems. Cytosine and guanine contain areas of
more negative ESP than the other nucleobases.
Thymine and uracil resemble each other having
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two negative sites on the oxygens separated by
a small positive site. Perhaps the most hetero-
geneous ESP is around adenine which exhibits
six areas of zero ESP near the molecular sur-
face, as compared to four (G, T, U) and two
(C). Apart from this, all of the nucleobases are
aromatic, which allows them to act as electron
donors via their pi-electrons above and below
their rings (not shown).
In nucleic acids, the situation is more com-
plicated than in nucleobases: the three-
dimensional structure of DNA and RNA is
electrostatically diverse due to the presence
of the phosphate backbone. For instance, the
DNA minor groove was shown to be more elec-
tronegative than the major groove.60 Thanks
to its plasticity, RNA may create folds with
even more unusual electrostatic characteristics.
Indeed, regions of strong negative electrostatic
potentials were exploited in designing efficient
TAR binders.61 Electrostatic interaction is also
the main driving force of aminoglycoside bind-
ing to the ribosome.62 Overall, NAs seem to
offer favorable electrostatics to attract positive
σ-holes on halogens. It remains elusive, how is
such ability employed in ligand recognition and
NA self-assembly.
Structural Survey Yields
Two Data Sets
To understand interaction preferences of halo-
gens we analyzed known NA structures. We
started with a broad set of X-ray structures
from the PDB (September 2016).27 Apart from
X-ray structures, the PDB also contains NA
structures determined by nuclear magnetic res-
onance (NMR) techniques. For two reasons,
we deliberately omitted those from our analy-
ses. First, we wanted to be consistent with the
strategies adopted by previous structural sur-
veys of X-bonds in protein-ligand complexes.
Second, there are indications that it may be
difficult to assess the quality of the deposited
NMR structural ensembles,63 which could com-
plicate the geometric characterization.
Within the X-ray structures, we searched for
complexes containing a nucleic acid and a halo-
gen atom (Cl, Br, or I). Fluorine was excluded
from the search due to its extremely low abil-
ity to form X-bonds in biological systems. The
selected structures comprise nucleic acids and
their complexes with other nucleic acids, low-
molecular ligands, and/or proteins. To get re-
liable geometric characteristics, only data with
the resolution better than 3.0 A˚ were consid-
ered. Note that the previous PDB surveys of
X-bonds in protein complexes used the same
resolution threshold.28,30
From the PDB, we obtained 672 files which
were subsequently filtered. We excluded struc-
tures containing halogens in the form of ions.
Following the recommendation of the Interna-
tional Union of Pure and Applied Chemistry,64
we selected X-bonds as the contacts between
halogens and electronegative atoms (N, O, P)
shorter than or equal to the sum of van der
Waals (vdW) radii65 (Tab. 1). The interac-
tions involving at least one of the two inter-
acting atoms with the crystal occupancy lower
than 0.5 were omitted. Because of the X-bond
directionality,23 we also required the angle of R–
X· · ·Y to be higher than 120◦. Same or similar
geometric criteria were used previously to define
biological X-bonds with proteins,28,29 although
the wider angular range was used in other stud-
ies as well.7,30
Table 1: Sums of van der Waals radii65 of
atomic pairs in A˚.
N O P
Cl 3.30 3.27 3.55
Br 3.40 3.37 3.65
I 3.53 3.50 3.78
We also searched for the X-bonds that are
formed with the aromatic systems of the nucle-
obases. To this aim, we considered only halogen
contacts closer than 5 A˚ to the aromatic plane
that make an angle between the plane normal
vector and the X–C bond smaller than 60◦.
In the end, we obtained a set of 21 X-bonds
that satisfy the data quality, chemical and ge-
ometric criteria. This amount is a rather low.
Scholfield et al. reported 760 protein complexes
with an X-bond in 2012, which stands for about
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Figure 2: 2D projections of the electrostatic potential (ESP) of the most common nucleobases A, C,
G, T, U onto the planes of their aromatic rings. Note the ESP in atomic units (au) was calculated
for the N-methylated analogs.
1 % of the 80,000 protein structures deposited
in the PDB at that time. The 21 X-bonds here
represent about 0.2 % of ca 9,000 structures
containing NA.
Hence to better capture possible geometric
properties of halogen interactions, we collected
a more extended set of complexes with a longer
interaction distance. An arbitrary threshold of
4 A˚ was chosen such that it is higher than the
X-bond length but still short enough to hint
for an attractive interaction. Within the ar-
ticle, the interactions are referred to as linear
contacts and they comprehend the X-bonds as
well. We found 72 linear contacts. Table 2 sum-
marizes various subsets of the PDB query.
The X-Bonds Favor Nucleo-
base· · ·Phosphate Pattern
Within the X-bond set, the variety of interact-
ing partners is low; 20 X-bonds involve a halo-
genated nucleobase, one X-bond is formed by
cisplatin chlorine. The set contains 19 X-bonds
with a phosphate oxygen as the electron donor;
further, there is one X-bonds with an aromatic
ring, and one with cytosine oxygen. Overall,
only two X-bonds do not concur with the dom-
inant nucleobase· · ·phosphate interaction pat-
tern.
The X-bond geometries are close to ideal.
The X-bond lengths are shorter than the sum
of the vdW radii by about 8 %, which con-
forms with the contractions reported for the
protein X-bonds.7 About 90 % of the X-bonds
are straighter than 160◦.
The shortest X-bond in the set belongs to a
structure of a Holliday junction; the X-bond
is found between a bromodeoxyuridine and a
phosphate oxygen of two neighboring residues
(Fig. 3a) (PDB: 2org, resolution 2.0 A˚).11 The
X-bond was shown to stabilize particular DNA
assembly in competition with H-bond. The
straightest X-bond also involves a brominated
uridine and phosphate oxygen (Fig. 3b) (PDB:
2bu1, resolution 2.2 A˚) in a complex of RNA
and phage MS2 coat protein66 and the overall
geometry is remarkably similar to the one found
in Holliday junction. Whereas the study on
Holliday junction fully appreciated the role of
X-bonding, in the latter case the specific inter-
action of the bromine remained unrecognized.
Figure 3: The shortest (a) and the straightest
(b) X-bonds found. Hydrogens were omitted
for clarity. Residues are labeled as BRU: 5-
bromouridine, dBRU: 5-bromo-2-deoxyuridine,
U: uridine, dA: deoxyadenosine.
What is important, we have identified no non-
covalent ligand involved in X-bonding. The
only non-nucleobase residue that participates
in an X-bonds is cisplatin covalently bound to
an adenine (PDB 5j4c, resolution 2.8 A˚67). It
is also the only halogen donor that forms an
X-bond with a pi-system, although the interac-
tion with one of the guanine nitrogens would
alone classify the interaction as X-bond. The
X-bond features superb geometric characteris-
tics (Fig. 4). Unlike proteins, in nucleic acids,
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Table 2: Analysis of the PDB. The contact is defined by the interatomic distance between a
halogen and oxygen, nitrogen, or phosphorus shorter than 4 A˚. The linear contact has the angle
R–X· · ·O/P/N higher than 120◦. X-bonds is a linear contact shorter than the sum of vdW radii.
Cl Br I sum
Files
PDB search count 402 204 66 672
Contains contact(s) 43 162 34 239
Contains contact(s) with NA building block 31 135 22 188
Contains linear contacts(s) with NA building block 22 29 2 53
Contains X-bond(s) with NA building block 2 17 2 21
Interactions
Number of contacts 611 1,319 205 2,135
Contacts with NA building block 43 315 41 399
Linear contacts with NA building block 22 48 2 72
X-bonds with NA building block 2 17 2 21
the halogen-pi interaction competes with pi − pi
interactions more often. Especially in dsDNA,
it is hardly conceivable that there is a space for
a halogen to attack the nucleobases from above
or below of their aromatic planes. The situ-
ation in RNAs might be more favorable, but
the single occurrence of such X-bond is hard to
generalize.
Figure 4: X-bond with an aromatic system be-
tween cisplatin (CPT) and a guanine (G). The
distance stands for the perpendicular distance
from the aromatic plane.
Interactions Longer Than X-
Bonds
Table 3 summarizes counts of various types of
interactions, and the statistics of the interac-
tion geometries of the set of 72 halogen linear
contacts.
In the NA complexes, the geometric quality
of the halogen interactions increases in the or-
der of Cl < Br < I. The interaction angles are
more linear for heavier halogens. Especially the
contacts of chlorine are rather bent with the
median angle of 141◦. The medians of the in-
teraction lengths (Tab. 3) decrease with the
increasing atomic number of the halogen. The
surveys on protein-ligand X-bonds28,29 revealed
the opposite trend, i.e. the increasing length of
X-bonds with the increasing atomic number of
the halogen involved. In this work (but also in
Ref. 28), the statistical sample might be insuffi-
cient to provide reliable statistics, which is true
especially for the two iodine X-bonds.
Fig. 5 shows the histograms of the interaction
lengths and angles. In the histogram of lengths,
the minor peak near 3.0 A˚, which is compara-
ble with the sum of the vdW radii, stands for
almost ideal X-bond length. There is a major
peak near 3.5 A˚ too. Two peaks also appear
in the histogram of interaction angles; around
140◦ and 170◦.
Each of the halogen subsets contributes to the
histograms with a different weight. Chlorine-
and bromine-containing complexes span the
whole range of interaction lengths. The two io-
dine complexes feature short interactions. The
situation with angles is different. Chlorine com-
plexes appear only in the region of lower inter-
action angles. The highest angle in the chlorine
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Table 3: Medians (med) and interquartile ranges (iqr) of geometric characteristics of interactions
involving various types of partners.
Halogen Count Length [A˚] (med±iqr) Angle [deg] (med±iqr)
chlorine 22 3.49±0.31 141±8
bromine 48 3.45±0.30 165±22
iodine 2 3.07±0.06 173±3
Electron Donor
N 21 3.47±0.28 140±11
non-backbone O 9 3.69±0.42 135±25
backbone O 42 3.41±0.45 166±8
Halogenated Residue
Halogenated nucleotide 51 3.43±0.43 165±23
Low-molecular ligand 21 3.50±0.29 140±7
Figure 5: Histograms of interaction lengths (a,
c) and interaction angles represented by the R–
X· · ·Y angle (b, d); color-coded according to the
halogen involved (a, b), or electron donating
atom (c, d).
subset is 154◦, so chlorine interactions are likely
weak. On the other hand, bromine complexes
are scattered across the whole range of angles
(Fig. 5b) with a cumulation around 170◦ (Fig.
6). The two iodine X-bonds are very straight
(X-bond angle higher than 170◦) suggesting a
strong interaction.
Figure 6: Interaction geometries in polar co-
ordinates color coded according to the halogen
(a), or the electron donor atom (b).
We analyzed the electron donors of halogen
interactions found in the NA complexes. The
backbone oxygen atom is the most common
one. We identified 51 linear contacts of halo-
gens with oxygen (71 %), and 21 with nitrogen
(29 %). Although we included phosphorus as an
electron donor in the search, no linear contact
was found. The actual occurrence of the oxygen
and nitrogen in NAs is roughly 2:1 (O:N), which
likely contributes to the dominance of the lin-
ear contacts with oxygen. Most of the nitrogen
interactions were found with chlorine, whereas
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bromine preferentially interacts with oxygen.
82 % of the all interacting oxygens belong to
the phosphate backbone. Unlike other oxygens
and nitrogens in NAs, the phosphate oxygens
carry a negative charge, which explains their
higher propensity to halogen σ-holes.
According to the electron-donating atoms,
the geometric quality of the interactions in-
creases in the order of non-backbone oxygen <
nitrogen < backbone oxygen (Tab. 3). The in-
teractions which employ a backbone oxygen are
typically shorter and straighter than the others.
We conclude that different interaction atoms
likely occur in different interaction geometries.
It is also apparent on a projection of the inter-
action geometries to the polar coordinates (Fig.
6). We observed no correlation between inter-
action lengths and the corresponding angles.
Halogenated Ligands Show
Sub-Optimal Interaction
Geometries
We did not find any X-bonded noncovalent lig-
ands in NA complexes. Nevertheless, in the set
of linear contacts we have found 15 unique lig-
ands – 14 chlorinated and one brominated. The
remaining interactions involve halogenated nu-
cleobases as halogen donors. The halogen in-
teractions of ligands are longer and less linear
compared to the interactions of halogenated nu-
cleobases (Tab. 3). The interaction angles de-
viate notably from linearity, which suggest that
such interactions do not play a critical role in
the NA-ligand recognition.
From the pharmaceutical point of view, the
low-molecular ligands are of higher interest
than the halogenated building blocks. Below
we discuss all of the instances among the linear-
contact data set which involve a low-molecular
ligand. Structural formulas of the ligands dis-
cussed are shown in Fig. 7.
Several halogenated compounds bind to the
bacterial ribosome. Chloramphenicol (1)46 is
a classic antibiotic compound that targets the
ribosomal A-site crevice in the 50S subunit
(PDB 1nji, resolution 3.0 A˚;68 4v7w, resolution
Figure 7: Structural formulas of several low-
molecular ligands or their building blocks that
participate in halogen interactions.
3.0 A˚69). 1 contains two aliphatic chlorines that
are activated by the nearby carbonyl group.
Two distinct binding orientations in two differ-
ent ribosomal system were proposed (T. ther-
mophilus 68 and H. marismortui 69) (Fig. 8).
The lengths of both chlorine interactions are
beyond the respective sums of the vdW radii
(about 3.3 A˚, Tab. 1), and quite bent. One
of the chlorines approaches either the ribose in-
ring oxygen (3.9 A˚, 154◦), or a guanine nitrogen
(3.8 A˚, 126◦), respectively. The geometries sug-
gest that the halogens interactions contribute
weakly to the complex stability.
Clindamycin (2)70 is another halogenated ri-
bosome binder71 (PDB 1yjn, resolution 3.0 A˚)
that binds into the 50S subunit (Fig. 9a) and
forms linear contacts. 2 contains one chlorine
that directs towards the sugar edge of guano-
sine. There is an interaction with guanine ni-
trogen (3.5 A˚, 148◦). At the same time, there
is a shorter but more bent contact with sugar
O2’ oxygen (3.1 A˚, 112◦).
7-chlorotetracycline (3)72 belongs to a class
of tetracycline antibiotics that bind into the ri-
bosomal 30S subunit. This class acts by pre-
venting correct processing of aminoacyl-tRNA.
Although no complex of 3 with the ribosome
9
Figure 8: Chloramphenicol 1 (CLM) interac-
tions in the 50S ribosomal subunit with guano-
sine (G) and uridine (U). Hydrogens were omit-
ted for clarity. The overlay of the two binding
poses found in T. thermophilus (PDB 1nji) and
H. marismortui (PDB 4v7w) into a single ref-
erence frame is shown in red and black, respec-
tively. Only residues within 7 A˚ from each of
the halogens are shown.
satisfies the data-set criteria, a complex with
an RNA aptamer does. The aptamer was de-
signed to bind 3 with sub-nanomolar affinity
(PDB 3egz, resolution 2.2 A˚73). It features an
interaction between a chlorine and a ribose oxy-
gen of a cytidine (Fig. 9b) (3.7 A˚, 151◦). Due
to the sub-optimal geometry, the role of halo-
gen interaction in complex stabilization is likely
marginal. Moreover, there are many other in-
termolecular interactions between the 3 and the
aptamer, such as a stacking of a planar part of 3
with a guanine, and an oxygen-magnesium co-
ordination (not shown). Those reduce the rel-
ative importance of the halogen contact even
more.
Recently, crystal structures of T. ther-
mophilus ribosomes with cisplatin37 (4 in
Fig. 9c) were resolved (PDB 5j4b, resolution
2.6 A˚; 5j4c, resolution 2.8 A˚67). Nine molecules
of cisplatin are covalently bound to the ribo-
some in place of one of the chlorines. Two of
the cisplatin residues were identified to interfere
with the mRNA tunnel and the GTPase site –
the places critical for the ribosome functions.67
One cisplatin out of the nine forms an X-bond
with a guanine pi-system (Fig. 4). Another cis-
platin directs with its chlorine in between two
stacked adenines with the shortest distance to
a nitrogen of 4.0 A˚ and angle 151◦. Another
nitrogen is about 4.2 A˚ far away and forms the
angle of 148◦ (Fig. 9c).
Our data set contains several ligands that
bind into the prototype foamy virus (PFV) in-
tasome, i.e. a complex of a viral integrase and
DNA. Such a system serves as a model for
HIV-1 integrase inhibition. Several inhibitors
were developed with a halogenated phenyl ring
(5 and 6) that form X-bonds with NAs.74–76
No difference in the interaction geometries was
found between 5 and 6 analogs. 5-analog in-
teractions show the best geometric characteris-
tics among the PFV ligands (but generally still
modest); the chlorine on 5 interacts with two
adenine nitrogens (Fig. 9d). While the contact
length of 3.3 A˚ is comparable with the sum of
vdW radii, the angle of 142◦ is far from the ideal
180◦. The other contact is 3.5 A˚-long and even
more bent (angle about 114◦). We add that
an aromatic fluorine activates the neighboring
chlorine by making its σ-hole more positive.23
The effect of fluorination on the ligand binding
affinity is not straightforward, however.77
We found only one brominated ligand with a
contacts shorter than 4 A˚. A brominated im-
idazole analog (7) binds into a G-quadruplex
formed within an RNA aptamer called Spinach
(PDB 4q9q, resolution 2.45 A˚).78 The Spinach
module allows a green-fluorescence-protein-like
functionality by selectively activating fluores-
cence of 7. 7 binds in a planar conformation
with a strong stacking interaction with adenine.
Besides this, it forms a contact with a phos-
phate oxygen of 3.5 A˚ under the angle of 137◦
(Fig. 9e).
Summary and Outlook
The role of X-bonding in drug development has
been emphasized for a decade. Nonetheless, the
knowledge-based design of halogenated drugs
that feature an X-bond with their biomolecular
targets is still a tedious task. Although there
have been published several pioneering studies
that involved protein targets,77,79,80 the nucleic
acids still lack a successful application.
In this work, we focused on X-ray structures
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Figure 9: Selected halogen interactions of ligand complexes. Clindamycin 2 (CLY) bound to the
ribosome (a), chlorotetracycline 3 (CTC) bound to an RNA aptamer (b), cisplatin 4 (CPT) bound
to ribosome (c), an intasome binder (ZZX) (d), a brominated imidazole analogue 7 (2ZZ) in an
RNA aptamer (e). Hydrogens were omitted for clarity. The interactions lengths and R–X· · ·Y
angles are provided.
of biomolecular complexes containing halogen
interactions with nucleic acids. The general
ability of nucleic acids to provide electron do-
nating groups to X-bonding has been confirmed
here. Using criteria recommended by IUPAC
for X-bond definition, we found 21 NA com-
plexes with the X-bond. We also analyzed in-
teractions of the halogen atoms longer than X-
bonds.
All but one of the X-bonds involved a halo-
genated nucleobase (preferably uridine). Halo-
genated nucleotides are often utilized in X-ray
crystallography, which explains their high oc-
currence in the NA complexes. The incorpora-
tion of heavy atoms such as bromine into the
structure helps to overcome the phase prob-
lem. Moreover, the halogenated nucleotides al-
ter the physico-chemical properties of the NAs
thus modulate the crystallization conditions; in
the classical theory this is due to their stacking
properties,81 but recently X-bonding has also
been shown to play a role.11 What is more, halo-
genated nucleobases may be also used in radi-
ation anti-cancer therapy as radiosensitizers.82
Although, the exact mechanism of the increased
radiosensitivity is not known, the changes in the
ionization potential brought by the halogens or
global structural changes associated with modi-
fied nucleobase pairing have been proposed.83,84
An important feature of X-bonds in NA com-
plexes is their preference towards backbone oxy-
gens. This is true also for the longer halogen
interactions. The phosphate oxygens tend to
form straighter and shorter X-bonds than other
electron donors, possibly due to their negative
charge.
In NA· · ·ligand noncovalent recognition, a va-
riety of interactions plays a role. H-bonding
and London dispersion-driven stacking interac-
tions belong to the classic interactions, comple-
mented by salt bridges, water-network disrup-
tions, or metal-ion interactions. Strictly speak-
ing, no noncovalent ligand has been found to
employ X-bonding in the NA binding (accord-
ing to the IUPAC recommendations). No X-
bonded NA ligand found is an intriguing fact,
which may be explained in two ways:
i) The X-bonding ligands may be inefficient
in NA recognition. If so, the halogenated lig-
ands that bind into NAs bind due to other kinds
of interactions that are stronger than X-bonds.
Our data support this hypothesis. All of the
halogen interactions of ligands found in the sur-
vey here show sub-optimal geometries. Given
11
the high X-bond directionality,85 the stabiliza-
tion energy of a complex reduces notably when
deviating from the ideal geometry. Hence, the
contribution to the stabilization of the NA com-
plexes is likely not dominant. Of course, there
are exceptions where X-bonding is the driving
interaction. For instance, it was proven that
a single X-bond/H-bond exchange might trans-
form the DNA conformation completely.11
ii) Medicinal chemists may under-appreciate
the role of X-bonding in the drug-design strate-
gies. Our data support also this hypothesis, be-
cause we found only a few halogenated ligands:
20 chlorinated, 8 brominated and one iodinated.
The current study on its own is unable to
dissect which reason is more likely. The start-
ing set of PDBs was biased towards the lighter
halogens, which are, however, less suitable for
strong X-bonds. For a better understanding
of the role of X-bonding, structural and func-
tional studies are required, especially of the
less-frequent brominated and iodinated com-
pounds.
The effects of halogens are not limited to
the X-bonding, though. The halogenation af-
fects the global electron distribution and conse-
quently many of the molecular properties. For
instance, Fanfrl´ık et al. demonstrated that sol-
vation/desolvation may compensate for favor-
able σ-hole· · ·lone pair interaction in halogen-
to-hydrogen substitution in a protein-ligand
complex.86 Also, a PDB survey of two protein
families revealed shortening on H-bonds proxi-
mal to ligand halogens.34 This corresponds with
the notion that halogenation increases the acid-
ity of proximal H-bond donors. Still, these ef-
fects in NAs are difficult to inspect with the
limited statistical sample of X-bonds here, and
of halogenated NA ligands in general.
Nevertheless, the current analyses may help
in designing novel X-bonded NA binders. Such
binders should contain a bromine or iodine to
form a strong X-bond. The ligand binding
should be directed to the vicinity of sugar-
phosphate backbone, for example to groove
or bulge regions. Consequently, such a lig-
and should likely not contain extensive aro-
matic systems that are prone to intercalation
into canonical helices. Systematic halogenation
of known pharmacologically active compounds
may be an optimal strategy to identify new
agents with enhanced activity, presumably sup-
ported by the specific X-bonds.
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